BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017;24:1073274817729245. [PMID: 28975830 DOI: 10.1177/1073274817729245] [Cited by in Crossref: 155] [Cited by in F6Publishing: 157] [Article Influence: 38.8] [Reference Citation Analysis]
Number Citing Articles
1 Yin L, Zhou L, Xu R. Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis. Front Mol Biosci 2020;7:599142. [PMID: 33681288 DOI: 10.3389/fmolb.2020.599142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Beyoğlu D, Idle JR. Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy. Metabolites 2020;10:E50. [PMID: 32012846 DOI: 10.3390/metabo10020050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
3 Rexha I, Laage-Gaupp F, Chapiro J, Miszczuk MA, van Breugel JMM, Lin M, Konstantinidis M, Duran R, Gebauer B, Georgiades C, Hong K, Nezami N. Role of 3D quantitative tumor analysis for predicting overall survival after conventional chemoembolization of intrahepatic cholangiocarcinoma. Sci Rep 2021;11:9337. [PMID: 33927226 DOI: 10.1038/s41598-021-88426-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Su M, Qiao KY, Xie XL, Zhu XY, Gao FL, Li CJ, Zhao DQ. Development of a Prognostic Signature Based on Single-Cell RNA Sequencing Data of Immune Cells in Intrahepatic Cholangiocarcinoma. Front Genet 2020;11:615680. [PMID: 33613623 DOI: 10.3389/fgene.2020.615680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jin H, Zhang M, Huang L, Hao J, Zhou L. Diagnosis of intrahepatic cholangiocarcinoma by Raman spectroscopy provides high efficiency: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e23900. [PMID: 33429751 DOI: 10.1097/MD.0000000000023900] [Reference Citation Analysis]
6 He L, Wang S, Ma X. The Influence of ICAM1 3'UTR Gene Polymorphism on the Occurrence and Metastasis of Primary Liver Cancer. Biomed Res Int 2021;2021:7377299. [PMID: 34869770 DOI: 10.1155/2021/7377299] [Reference Citation Analysis]
7 Zhang J, Wu L, Liu J, Lin M. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review. Immunotherapy 2020;12:555-61. [PMID: 32372672 DOI: 10.2217/imt-2019-0100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. Jpn J Clin Oncol 2020;50:1370-9. [PMID: 32719873 DOI: 10.1093/jjco/hyaa130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
9 Cheng N, Khoo N, Chung AYF, Goh BKP, Cheow PC, Chow PKH, Lee SY, Ooi LL, Jeyaraj PR, Kam JH, Koh YX, Chan CY, Teo JY. Pre-operative Imaging Characteristics in Histology-Proven Resected Intrahepatic Cholangiocarcinoma. World J Surg 2020;44:3862-7. [PMID: 32720003 DOI: 10.1007/s00268-020-05698-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Bayik D, Lauko AJ, Roversi GA, Serbinowski E, Acevedo-Moreno LA, Lanigan C, Orujov M, Lo A, Alban TJ, Kim A, Silver DJ, Nagy LE, Brown JM, Allende DS, Aucejo FN, Lathia JD. Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles.Sci Rep. 2020;10:18848. [PMID: 33139767 DOI: 10.1038/s41598-020-75881-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Su ZJ, Liu XY, Zhang JH, Ke SY, Fei HJ. Neurotensin promotes cholangiocarcinoma metastasis via the EGFR/AKT pathway. Gene 2019;687:143-50. [PMID: 30359740 DOI: 10.1016/j.gene.2018.10.062] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
12 Alipour Talesh G, Trézéguet V, Merched A. Hepatocellular Carcinoma and Statins. Biochemistry 2020;59:3393-400. [PMID: 32865979 DOI: 10.1021/acs.biochem.0c00476] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Borges KA, Dai J, Parikh ND, Schwartz M, Nguyen MH, Roberts LR, Befeler AS, Srivastava S, Rinaudo JA, Feng Z, Marrero JA, Reddy KR. Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Institute's Early Detection Research Network. Contemp Clin Trials 2019;76:49-54. [PMID: 30439517 DOI: 10.1016/j.cct.2018.11.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
14 Vogel A, Frenette C, Sung M, Daniele B, Baron A, Chan SL, Blanc JF, Tamai T, Ren M, Lim HJ, Palmer DH, Takami Y, Kudo M. Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:510-21. [PMID: 34721512 DOI: 10.1159/000516490] [Reference Citation Analysis]
15 Imai K, Yamashita YI, Nakao Y, Matsumoto T, Kinoshita S, Yusa T, Kitano Y, Kaida T, Hayashi H, Baba H. Is Portal Vein Embolization Followed by Hepatectomy for Hepatocellular Carcinoma Justified in Patients with Impaired Liver Function? Ann Surg Oncol 2021;28:854-62. [PMID: 32740735 DOI: 10.1245/s10434-020-08960-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Carlessi R, Köhn-gaone J, Olynyk JK, Tirnitz-parker JEE; School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Bentley, WA, Australia, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Bentley, WA, Australia, Fiona Stanley and Fremantle Hospitals, Fremantle and Murdoch, WA, Australia, School of Health and Medical Sciences, Edith Cowan University, Joondalup, WA, Australia, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Bentley, WA, Australia, Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, The University of Western Australia, Crawley WA, Australia. Mouse Models of Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 69-94. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Tian M, Zhou Y, Qu W, Liu W, Jin L, Jiang X, Wang H, Tao C, Zhou P, Fang Y, Ding Z, Peng Y, Zhou J, Fan J, Shi Y. Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. Cancer Immunol Immunother 2019;68:1369-78. [DOI: 10.1007/s00262-019-02371-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
18 Darbà J, Marsà A. Analysis of hospital incidence and direct medical costs of intrahepatic cholangiocarcinoma in Spain (2000-2018). Expert Rev Pharmacoecon Outcomes Res 2021;21:425-31. [PMID: 33161795 DOI: 10.1080/14737167.2021.1842201] [Reference Citation Analysis]
19 Cai L, Jin X, Zhang J, Li L, Zhao J. Metformin suppresses Nrf2-mediated chemoresistance in hepatocellular carcinoma cells by increasing glycolysis. Aging (Albany NY) 2020;12:17582-600. [PMID: 32927432 DOI: 10.18632/aging.103777] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Yang Z, Abdrakhimov B, Wang S, Xie QF, Zheng SS. Multidisciplinary Treatment of Advanced Hepatocellular Carcinoma. Case Rep Gastroenterol 2020;14:98-102. [PMID: 32231509 DOI: 10.1159/000506185] [Reference Citation Analysis]
21 Shirasaka T, Kojima T, Funama Y, Sakai Y, Kondo M, Mikayama R, Hamasaki H, Kato T, Ushijima Y, Asayama Y, Nishie A. Image quality improvement with deep learning-based reconstruction on abdominal ultrahigh-resolution CT: A phantom study. J Appl Clin Med Phys 2021;22:286-96. [PMID: 34159736 DOI: 10.1002/acm2.13318] [Reference Citation Analysis]
22 Zaccari P, Cardinale V, Severi C, Pedica F, Carpino G, Gaudio E, Doglioni C, Petrone MC, Alvaro D, Arcidiacono PG, Capurso G. Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas. World J Gastroenterol 2019; 25(31): 4343-4359 [PMID: 31496617 DOI: 10.3748/wjg.v25.i31.4343] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
23 Yang SW, Chen WL, Wu WT, Wang CC. Investigation on returning to work in liver cancer survivors in Taiwan: a 5-year follow-up study. BMC Public Health 2021;21:1846. [PMID: 34641825 DOI: 10.1186/s12889-021-11872-9] [Reference Citation Analysis]
24 Li X, Yang J, Yang X, Cao T. Dysregulated circ_0004913, circ_0008160, circ_0000517, and their potential as biomarkers for disease monitoring and prognosis in hepatocellular carcinoma. J Clin Lab Anal 2021;35:e23785. [PMID: 34018640 DOI: 10.1002/jcla.23785] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ichikawa S, Isoda H, Shimizu T, Tamada D, Taura K, Togashi K, Onishi H, Motosugi U. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study. Eur Radiol 2020;30:5992-6002. [PMID: 32500195 DOI: 10.1007/s00330-020-06972-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Manmadhan S, Ehmer U. Hippo Signaling in the Liver - A Long and Ever-Expanding Story. Front Cell Dev Biol 2019;7:33. [PMID: 30931304 DOI: 10.3389/fcell.2019.00033] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
27 Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87. [PMID: 33579427 DOI: 10.1016/bs.acr.2020.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Hajiasgharzadeh K, Somi MH, Shanehbandi D, Mokhtarzadeh A, Baradaran B. Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma. J Cell Physiol 2019;234:3263-76. [PMID: 30362510 DOI: 10.1002/jcp.27015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
29 Hou Y, Wang S, Gao M, Chang J, Sun J, Qin L, Li A, Lv F, Lou J, Zhang Y, Zhao Y. Interferon-Induced Transmembrane Protein 3 Expression Upregulation Is Involved in Progression of Hepatocellular Carcinoma. Biomed Res Int 2021;2021:5612138. [PMID: 33816616 DOI: 10.1155/2021/5612138] [Reference Citation Analysis]
30 Shi JF, Cao M, Wang Y, Bai FZ, Lei L, Peng J, Feletto E, Canfell K, Qu C, Chen W. Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer 2021;148:1051-65. [PMID: 32997794 DOI: 10.1002/ijc.33313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
31 Li F, Li Q, Liu Y, Han J, Zheng W, Huang Y, Zheng X, Cao L, Zhou J. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017. Eur Radiol 2020;30:461-70. [DOI: 10.1007/s00330-019-06317-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
32 El‐serag HB. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 758-72. [DOI: 10.1002/9781119436812.ch59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
33 Abdel-Rahman O. Treatment choices and outcomes of non-metastatic hepatocellular carcinoma patients in relationship to neighborhood socioeconomic status: a population-based study. Int J Clin Oncol. 2020;25:861-866. [PMID: 31953780 DOI: 10.1007/s10147-020-01616-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
34 Liu M, Chen J, Huang R, Huang J, Li L, Li Y, Qin M, Qin W, Nong H, Ding K. Imaging features of intrahepatic cholangiocarcinoma mimicking a liver abscess: an analysis of 8 cases. BMC Gastroenterol 2021;21:427. [PMID: 34772340 DOI: 10.1186/s12876-021-02002-1] [Reference Citation Analysis]
35 Ding SY, Wang MT, Dai DF, Peng JL, Wu WL. Salidroside induces apoptosis and triggers endoplasmic reticulum stress in human hepatocellular carcinoma. Biochem Biophys Res Commun 2020;527:1057-63. [PMID: 32439176 DOI: 10.1016/j.bbrc.2020.05.066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Jogi S, Varanai R, Bantu SS, Manne A. Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncol Rev 2020;14:515. [PMID: 33425223 DOI: 10.4081/oncol.2020.515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, Taniguchi K. Inflammation-Induced Tumorigenesis and Metastasis. Int J Mol Sci 2021;22:5421. [PMID: 34063828 DOI: 10.3390/ijms22115421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer.Lancet. 2021;397:428-444. [PMID: 33516341 DOI: 10.1016/S0140-6736(21)00153-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 23.0] [Reference Citation Analysis]
39 Song C, Zhang J, Zhao Z, Yang Y, Meng D, Wang J, Guo C, Yuan C. DLEU1: A Functional Long Noncoding RNA in Tumorigenesis. Curr Pharm Des 2020;26:1742-8. [PMID: 31969095 DOI: 10.2174/1381612826666200122145305] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, Guo P, Hao B, Fu H, Xie C, Lin Q, Wu H, Sun L, Chen H. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging 2021;48:1604-17. [DOI: 10.1007/s00259-020-05095-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
41 Li J, Zhao T, Li J, Shen J, Jia L, Zhu B, Dang L, Ma C, Liu D, Mu F, Hu L, Sun S. Precision N-glycoproteomics reveals elevated LacdiNAc as a novel signature of intrahepatic cholangiocarcinoma. Mol Oncol 2021. [PMID: 34855283 DOI: 10.1002/1878-0261.13147] [Reference Citation Analysis]
42 Cressman ENK, Guo C. First In Vivo Test of Thermoembolization: Turning Tissue Against Itself Using Transcatheter Chemistry in a Porcine Model. Cardiovasc Intervent Radiol 2018;41:1611-7. [PMID: 29872896 DOI: 10.1007/s00270-018-2003-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
43 Vaughan TL, Onstad L, Dai JY. Interactive decision support for esophageal adenocarcinoma screening and surveillance. BMC Gastroenterol 2019;19:109. [PMID: 31248371 DOI: 10.1186/s12876-019-1022-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
44 Hu Y, Lin H, Hao M, Zhou Y, Chen Q, Chen Z. Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study. Cancer Manag Res 2020;12:5345-51. [PMID: 32753952 DOI: 10.2147/CMAR.S254955] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Gillman R, Lopes Floro K, Wankell M, Hebbard L. The role of DNA damage and repair in liver cancer. Biochim Biophys Acta Rev Cancer 2021;1875:188493. [PMID: 33316376 DOI: 10.1016/j.bbcan.2020.188493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Li L, Li X, Zhang Q, Ye T, Zou S, Yan J. EIF5A expression and its role as a potential diagnostic biomarker in hepatocellular carcinoma. J Cancer 2021;12:4774-9. [PMID: 34234848 DOI: 10.7150/jca.58168] [Reference Citation Analysis]
47 Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, Zhu AX. Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. Hepatology 2019;69:1803-15. [PMID: 30251463 DOI: 10.1002/hep.30289] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 20.3] [Reference Citation Analysis]
48 Lin Y, Chen BM, Yu XL, Yi HC, Niu JJ, Li SL. Suppressed Expression of CXCL14 in Hepatocellular Carcinoma Tissues and Its Reduction in the Advanced Stage of Chronic HBV Infection. Cancer Manag Res 2019;11:10435-43. [PMID: 31849533 DOI: 10.2147/CMAR.S220528] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Guo LQ, Sun HW, Zhang CY, Feng Y, Teng XL, Qu YK. Efficacy of fluoxetine for anorexia nervosa caused by chemotherapy in patients with cholangiocarcinoma. Medicine (Baltimore) 2019;98:e15945. [PMID: 31192931 DOI: 10.1097/MD.0000000000015945] [Reference Citation Analysis]
50 Ding Y, Han X, Sun Z, Tang J, Wu Y, Wang W. Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy. Front Oncol 2021;11:691380. [PMID: 34527576 DOI: 10.3389/fonc.2021.691380] [Reference Citation Analysis]
51 Hajiasgharzadeh K, Sadigh-Eteghad S, Mansoori B, Mokhtarzadeh A, Shanehbandi D, Doustvandi MA, Asadzadeh Z, Baradaran B. Alpha7 nicotinic acetylcholine receptors in lung inflammation and carcinogenesis: Friends or foes? J Cell Physiol 2019. [PMID: 30701535 DOI: 10.1002/jcp.28220] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
52 Mosconi C, Solaini L, Vara G, Brandi N, Cappelli A, Modestino F, Cucchetti A, Golfieri R. Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis. Cardiovasc Intervent Radiol 2021;44:728-38. [PMID: 33709272 DOI: 10.1007/s00270-021-02800-w] [Reference Citation Analysis]
53 Chen Y, Wang W. Differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced ultrasound: A systematic review and meta-analysis. Clin Hemorheol Microcirc 2021. [PMID: 33935070 DOI: 10.3233/CH-211145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Feng L, Wang Y, Wang X, An S, Aizimuaji Z, Tao C, Zhang K, Cheng S, Wu J, Xiao T, Rong W. Integrated analysis of the rhesus monkey liver transcriptome during development and human primary HCC AFP-related gene expression. Mol Ther Nucleic Acids 2021;25:406-15. [PMID: 34484865 DOI: 10.1016/j.omtn.2021.06.004] [Reference Citation Analysis]
55 Zhou D, Gao B, Yang Q, Kong Y, Wang W. Integrative Analysis of ceRNA Network Reveals Functional lncRNAs in Intrahepatic Cholangiocarcinoma. Biomed Res Int 2019;2019:2601271. [PMID: 31886187 DOI: 10.1155/2019/2601271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
56 Zheng W, Shen GL, Xu KY, Yin QQ, Hui TC, Zhou ZW, Xu CA, Wang SH, Wu WH, Shi LF, Pan HY. Lnc524369 promotes hepatocellular carcinoma progression and predicts poor survival by activating YWHAZ-RAF1 signaling. World J Gastrointest Oncol 2022; 14(1): 253-264 [DOI: 10.4251/wjgo.v14.i1.253] [Reference Citation Analysis]
57 Yassin NYS, AbouZid SF, El-Kalaawy AM, Ali TM, Almehmadi MM, Ahmed OM. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways. Biomed Pharmacother 2021;145:112409. [PMID: 34781148 DOI: 10.1016/j.biopha.2021.112409] [Reference Citation Analysis]
58 Fahrenholtz SJ, Guo C, MacLellan CJ, Yung JP, Hwang KP, Layman RR, Stafford RJ, Cressman E. Temperature mapping of exothermic in situ chemistry: imaging of thermoembolization via MR. Int J Hyperthermia 2019;36:730-8. [PMID: 31362538 DOI: 10.1080/02656736.2019.1635274] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
59 Yu K, Tang J, Wu JL, Li B, Wu SN, Zhang MY, Li QY, Zhang LJ, Pan YC, Ge QM, Shu HY, Shao Y. Risk factors for intraocular metastasis of primary liver cancer in diabetic patients: Alpha-fetoprotein and cancer antigen 125. World J Diabetes 2021; 12(2): 158-169 [PMID: 33594335 DOI: 10.4239/wjd.v12.i2.158] [Reference Citation Analysis]
60 Golob-Schwarzl N, Bettermann K, Mehta AK, Kessler SM, Unterluggauer J, Krassnig S, Kojima K, Chen X, Hoshida Y, Bardeesy NM, Müller H, Svendova V, Schimek MG, Diwoky C, Lipfert A, Mahajan V, Stumptner C, Thüringer A, Fröhlich LF, Stojakovic T, Nilsson KPR, Kolbe T, Rülicke T, Magin TM, Strnad P, Kiemer AK, Moriggl R, Haybaeck J. High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. Transl Oncol 2019;12:256-68. [PMID: 30439626 DOI: 10.1016/j.tranon.2018.10.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
61 Pinheiro PS, Medina HN, Callahan KE, Jones PD, Brown CP, Altekruse SF, McGlynn KA, Kobetz EN. The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida. Liver Int 2020;40:1201-10. [PMID: 32087002 DOI: 10.1111/liv.14409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
62 Massironi S, Pilla L, Elvevi A, Longarini R, Rossi RE, Bidoli P, Invernizzi P. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. Cells 2020;9:E688. [PMID: 32168869 DOI: 10.3390/cells9030688] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
63 Shahzadi I, Ali Z, Baek SH, Mirza B, Ahn KS. Assessment of the Antitumor Potential of Umbelliprenin, a Naturally Occurring Sesquiterpene Coumarin. Biomedicines 2020;8:E126. [PMID: 32443431 DOI: 10.3390/biomedicines8050126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
64 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1126] [Cited by in F6Publishing: 1057] [Article Influence: 375.3] [Reference Citation Analysis]
65 Ahmed T, Shahid M, Noman M, Bilal Khan Niazi M, Zubair M, Almatroudi A, Khurshid M, Tariq F, Mumtaz R, Li B. Bioprospecting a native silver-resistant Bacillus safensis strain for green synthesis and subsequent antibacterial and anticancer activities of silver nanoparticles. J Adv Res 2020;24:475-83. [PMID: 32566283 DOI: 10.1016/j.jare.2020.05.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
66 Delhaye C, Hendlisz A, Vouche M. Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma. Curr Opin Oncol 2019;31:339-45. [PMID: 30896451 DOI: 10.1097/CCO.0000000000000539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Coon C, Berger N, Eastwood D, Tsai S, Christians K, Mogal H, Clarke C, Gamblin TC. Primary Liver Cancer: An NCDB Analysis of Overall Survival and Margins After Hepatectomy. Ann Surg Oncol 2020;27:1156-63. [DOI: 10.1245/s10434-019-07843-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
68 Imai K, Takai K, Miwa T, Maeda T, Hanai T, Shirakami Y, Suetsugu A, Shimizu M. Higher Accumulation of Visceral Adipose Tissue Is an Independent Risk Factor for Hepatocellular Carcinoma among Viral Hepatitis Patients with Non-Cirrhotic Livers. Cancers (Basel) 2021;13:5980. [PMID: 34885089 DOI: 10.3390/cancers13235980] [Reference Citation Analysis]
69 Abrantes AM, Pires AS, Monteiro L, Teixo R, Neves AR, Tavares NT, Marques IA, Botelho MF. Tumour functional imaging by PET. Biochim Biophys Acta Mol Basis Dis 2020;1866:165717. [PMID: 32035103 DOI: 10.1016/j.bbadis.2020.165717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
70 Cullaro G, Rubin JB, Mehta N, Lai JC. Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma. Liver Transpl 2020;26:349-58. [PMID: 31610089 DOI: 10.1002/lt.25662] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
71 Laohawetwanit T, Klaikaew N. Pathological aspects of mucinous cholangiocarcinoma: A single-center experience and systematic review. Pathol Int 2020;70:661-70. [PMID: 32638458 DOI: 10.1111/pin.12983] [Reference Citation Analysis]
72 Conci S, Cipriani F, Donadon M, Marchitelli I, Ardito F, Famularo S, Perri P, Iaria M, Ansaloni L, Zanello M, La Barba G, Patauner S, Pinotti E, Molfino S, Germani P, Romano M, Sciannamea I, Ferrari C, Manzoni A, Troci A, Fumagalli L, Delvecchio A, Floridi A, Memeo R, Chiarelli M, Crespi M, Zimmitti G, Griseri G, Antonucci A, Zanus G, Tarchi P, Baiocchi GL, Zago M, Frena A, Ercolani G, Jovine E, Maestri M, Valle RD, Grazi GL, Romano F, Giuliante F, Torzilli G, Aldrighetti L, Ruzzenente A; He.RC.O.Le.S Group. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC. Eur J Surg Oncol 2021:S0748-7983(21)00636-3. [PMID: 34325939 DOI: 10.1016/j.ejso.2021.07.015] [Reference Citation Analysis]
73 Qi Y, Fan L, Ran D, Xu J, Wang Y, Wu J, Zhang Z. Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Oncol 2021;2021:7764817. [PMID: 34691178 DOI: 10.1155/2021/7764817] [Reference Citation Analysis]
74 Ashhab AA, Rodin H, Powell J, Debes JD. Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA. Eur J Gastroenterol Hepatol 2019;31:24-8. [PMID: 30024491 DOI: 10.1097/MEG.0000000000001212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Pinheiro D, Dias I, Ribeiro Silva K, Stumbo AC, Thole A, Cortez E, de Carvalho L, Weiskirchen R, Carvalho S. Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview. Cells 2019;8:E1339. [PMID: 31671842 DOI: 10.3390/cells8111339] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
76 Jafri W, Kamran M. Hepatocellular Carcinoma in Asia: A Challenging Situation. Euroasian J Hepatogastroenterol 2019;9:27-33. [PMID: 31988864 DOI: 10.5005/jp-journals-10018-1292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
77 Mao B, Ma J, Duan S, Xia Y, Tao Y, Zhang L. Preoperative classification of primary and metastatic liver cancer via machine learning-based ultrasound radiomics. Eur Radiol 2021;31:4576-86. [PMID: 33447862 DOI: 10.1007/s00330-020-07562-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Miao Y, Zhang Y, Yin L. Trends in hepatocellular carcinoma research from 2008 to 2017: a bibliometric analysis. PeerJ 2018;6:e5477. [PMID: 30128213 DOI: 10.7717/peerj.5477] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
79 Ran X, Luo J, Zuo C, Huang Y, Sui Y, Cen J, Tang S. Developing metabolic gene signatures to predict intrahepatic cholangiocarcinoma prognosis and mining a miRNA regulatory network. J Clin Lab Anal 2021;:e24107. [PMID: 34871464 DOI: 10.1002/jcla.24107] [Reference Citation Analysis]
80 Spolverato G, Bagante F, Tsilimigras D, Ejaz A, Cloyd J, Pawlik TM. Management and outcomes among patients with mixed hepatocholangiocellular carcinoma: A population-based analysis. J Surg Oncol. 2019;119:278-287. [PMID: 30554420 DOI: 10.1002/jso.25331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
81 Dandachi D, Hassan M, Kaseb A, Angelidakis G, Torres HA. Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer. J Hepatocell Carcinoma 2018;5:81-6. [PMID: 30123783 DOI: 10.2147/JHC.S164568] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
82 Zhang Z, Xu L, Sun C. Comprehensive characterization of cancer genes in hepatocellular carcinoma genomes. Oncol Lett. 2018;15:1503-1510. [PMID: 29434842 DOI: 10.3892/ol.2017.7521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
83 Tsujie M, Iwai T, Kubo S, Ura T, Hatano E, Sakai D, Takeda Y, Kaibori M, Kobayashi T, Katanuma A, Katayose Y, Fukase K. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma. Jpn J Clin Oncol 2021;51:911-7. [PMID: 33822966 DOI: 10.1093/jjco/hyab029] [Reference Citation Analysis]
84 Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD. Hepatology. 2020;72:1605-1616. [PMID: 32043613 DOI: 10.1002/hep.31173] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 34.5] [Reference Citation Analysis]
85 Jeong S, Ge Y, Chen J, Gao Q, Luo G, Zheng B, Sha M, Shen F, Cheng Q, Sui C, Liu J, Wang H, Xia Q, Chen L. Latent Risk Intrahepatic Cholangiocarcinoma Susceptible to Adjuvant Treatment After Resection: A Clinical Deep Learning Approach.Front Oncol. 2020;10:143. [PMID: 32140448 DOI: 10.3389/fonc.2020.00143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
86 Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. World J Gastroenterol 2021; 27(17): 2025-2038 [PMID: 34007137 DOI: 10.3748/wjg.v27.i17.2025] [Reference Citation Analysis]
87 Ganai SA, Sheikh FA, Baba ZA, Mir MA, Mantoo MA, Yatoo MA. Anticancer activity of the plant flavonoid luteolin against preclinical models of various cancers and insights on different signalling mechanisms modulated. Phytotherapy Research 2021;35:3509-32. [DOI: 10.1002/ptr.7044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
88 Chang KP, Lin SH, Chu YW. Artificial intelligence in gastrointestinal radiology: A review with special focus on recent development of magnetic resonance and computed tomography. Artif Intell Gastroenterol 2021; 2(2): 27-41 [DOI: 10.35712/aig.v2.i2.27] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases: Marrero et al. Hepatology 2018;68:723-50. [DOI: 10.1002/hep.29913] [78495111110.1002/hep.29913','', '1948-5182')">Reference Citation Analysis]
91 Yang K, Jia M, Cheddah S, Zhang Z, Wang W, Li X, Wang Y, Yan C. Peptide ligand-SiO2 microspheres with specific affinity for phosphatidylserine as a new strategy to isolate exosomes and application in proteomics to differentiate hepatic cancer. Bioactive Materials 2021. [DOI: 10.1016/j.bioactmat.2021.12.017] [Reference Citation Analysis]
92 Kornberg A, Friess H. 18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches. Therap Adv Gastroenterol 2019;12:1756284819836205. [PMID: 30915167 DOI: 10.1177/1756284819836205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Hemming AW. Biliary Tract and Primary Liver Tumors. Surgical Oncology Clinics of North America 2019;28:519-38. [DOI: 10.1016/j.soc.2019.06.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
94 Becker-assmann J, Fard-aghaie MH, Kantas A, Makridis G, Reese T, Wagner KC, Petersen J, Buggisch P, Stang A, von Hahn T, Oldhafer KJ. Diagnostische und prognostische Bedeutung des α-Feto-Proteins beim hepatozellulären Karzinom. Chirurg 2020;91:769-77. [DOI: 10.1007/s00104-020-01118-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
95 Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, Eguchi Y, Wong VW, Negro F, Yilmaz Y, Romero-Gomez M, George J, Ahmed A, Wong R, Younossi I, Ziayee M, Afendy A;  Global Nonalcoholic Steatohepatitis Council. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol. 2019;17:748-755.e3. [PMID: 29908364 DOI: 10.1016/j.cgh.2018.05.057] [Cited by in Crossref: 219] [Cited by in F6Publishing: 217] [Article Influence: 54.8] [Reference Citation Analysis]
96 Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Cressman ENK, Guo C, Karbasian N. Image-guided chemistry altering biology: An in vivo study of thermoembolization. PLoS One 2018;13:e0200471. [PMID: 30011300 DOI: 10.1371/journal.pone.0200471] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
98 Wu X, Ma W, Mei C, Chen X, Yao Y, Liu Y, Qin X, Yuan Y. Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment. J Exp Clin Cancer Res. 2020;39:97. [PMID: 32487115 DOI: 10.1186/s13046-020-01603-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
99 Cressman ENK, Guo C. Feasibility study using tissue as reagent for cancer therapy: endovascular ablation via thermochemistry. Converg Sci Phys Oncol 2018;4:025003. [DOI: 10.1088/2057-1739/aab905] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
100 Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment. Int J Mol Sci 2019;20:E605. [PMID: 30704150 DOI: 10.3390/ijms20030605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
101 Feng J, Wu L, Ji J, Chen K, Yu Q, Zhang J, Chen J, Mao Y, Wang F, Dai W, Xu L, Wu J, Guo C. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma. J Exp Clin Cancer Res 2019;38:204. [PMID: 31101057 DOI: 10.1186/s13046-019-1194-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
102 Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol 2021;13:17588359211036544. [PMID: 34377158 DOI: 10.1177/17588359211036544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Yang YM, Kim SY, Seki E. Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets. Semin Liver Dis. 2019;39:26-42. [PMID: 30809789 DOI: 10.1055/s-0038-1676806] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 18.7] [Reference Citation Analysis]
104 Kang CM, Suh KS, Yi NJ, Hong TH, Park SJ, Ahn KS, Hayashi H, Choi SB, Jeong CY, Takahara T, Shiozaki S, Roh YH, Yu HC, Fukumoto T, Matsuyama R, Naoki U, Hashida K, Seo HI, Okabayashi T, Kitajima T, Satoi S, Nagano H, Kim H, Taira K, Kubo S, Choi DW. Should Lymph Nodes Be Retrieved in Patients with Intrahepatic Cholangiocarcinoma? A Collaborative Korea-Japan Study. Cancers (Basel) 2021;13:445. [PMID: 33503932 DOI: 10.3390/cancers13030445] [Reference Citation Analysis]
105 Zhang L, Wang W, Liu L, Zhang Y, Zhang X. Peroxisome proliferator-activated receptor gamma coactivator 1-alpha protects a fibrotic liver from partial hepatectomy-induced advanced liver injury through regulating cell cycle arrest. Basic Clin Pharmacol Toxicol 2021. [PMID: 34845850 DOI: 10.1111/bcpt.13697] [Reference Citation Analysis]
106 Tseng GW, Lin MC, Lai SW, Peng CY, Chuang PH, Su WP, Kao JT, Lai HC. Do peripartum and postmenopausal women with primary liver cancer have a worse prognosis? A nationwide cohort in Taiwan. World J Hepatol 2021; 13(11): 1766-1776 [PMID: 34904044 DOI: 10.4254/wjh.v13.i11.1766] [Reference Citation Analysis]
107 Nguyen L, Jager M, Lieshout R, de Ruiter PE, Locati MD, Besselink N, van der Roest B, Janssen R, Boymans S, de Jonge J, IJzermans JNM, Doukas M, Verstegen MMA, van Boxtel R, van der Laan LJW, Cuppen E, Kuijk E. Precancerous liver diseases do not cause increased mutagenesis in liver stem cells. Commun Biol 2021;4:1301. [PMID: 34795391 DOI: 10.1038/s42003-021-02839-y] [Reference Citation Analysis]
108 Guo X, Shen W. Latest evidence on immunotherapy for cholangiocarcinoma.Oncol Lett. 2020;20:381. [PMID: 33154779 DOI: 10.3892/ol.2020.12244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
109 Kozak MM, Toesca DAS, von Eyben R, Pollom EL, Chang DT. Stereotactic Body Radiation Therapy for Cholangiocarcinoma: Optimizing Locoregional Control with Elective Nodal Irradiation. Adv Radiat Oncol. 2020;5:77-84. [PMID: 32051893 DOI: 10.1016/j.adro.2019.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
110 Virani S, Akers A, Stephenson K, Smith S, Kennedy L, Alpini G, Francis H. Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma. J Liver 2018;7:231. [PMID: 30613437 DOI: 10.4172/2167-0889.1000231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
111 Thylur RP, Roy SK, Shrivastava A, LaVeist TA, Shankar S, Srivastava RK. Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. JGH Open 2020;4:351-9. [PMID: 32514436 DOI: 10.1002/jgh3.12336] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
112 Yang HG, Wang TP, Hu SA, Hu CZ, Jiang CH, He Q. Long Non-coding RNA SNHG12, a New Therapeutic Target, Regulates miR-199a-5p/Klotho to Promote the Growth and Metastasis of Intrahepatic Cholangiocarcinoma Cells. Front Med (Lausanne) 2021;8:680378. [PMID: 34239888 DOI: 10.3389/fmed.2021.680378] [Reference Citation Analysis]
113 Abbasi BH, Nazir M, Muhammad W, Hashmi SS, Abbasi R, Rahman L, Hano C. A Comparative Evaluation of the Antiproliferative Activity against HepG2 Liver Carcinoma Cells of Plant-Derived Silver Nanoparticles from Basil Extracts with Contrasting Anthocyanin Contents. Biomolecules 2019;9:E320. [PMID: 31366167 DOI: 10.3390/biom9080320] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
114 Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Reference Citation Analysis]
115 Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, Jeong WK, Park MS, Kudo N, Lee MW, Kamata K, Iijima H, Kim SY, Numata K, Sugimoto K, Maruyama H, Sumino Y, Ogawa C, Kitano M, Joo I, Arita J, Liang JD, Lin HM, Nolsoe C, Gilja OH, Kudo M. The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid. Ultrasonography 2020;39:191-220. [PMID: 32447876 DOI: 10.14366/usg.20057] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
116 Pei SN, Liao CK, Chen YS, Tseng CH, Hung CM, Chiu CC, Hsieh MC, Tsai YF, Liao HY, Liu WC, Rau KM. A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study. Cancers (Basel) 2021;13:3831. [PMID: 34359732 DOI: 10.3390/cancers13153831] [Reference Citation Analysis]
117 A S, Wu H, Wang X, Wang X, Yang J, Xia L, Xia Y. Value of glycogen synthase 2 in intrahepatic cholangiocarcinoma prognosis assessment and its influence on the activity of cancer cells. Bioengineered 2021;12:12167-78. [PMID: 34783271 DOI: 10.1080/21655979.2021.2005224] [Reference Citation Analysis]
118 Kobayashi T, Ichimura-Shimizu M, Oya T, Ogawa H, Matsumoto M, Morimoto Y, Sumida S, Kakimoto T, Yamashita M, Sutoh M, Toyohara S, Hokao R, Cheng C, Tsuneyama K. Neonatal streptozotocin treatment rapidly causes different subtype of hepatocellular carcinoma without persistent hyperglycemia in 4CS mice fed on a normal diet. Pathol Res Pract 2021;225:153559. [PMID: 34325313 DOI: 10.1016/j.prp.2021.153559] [Reference Citation Analysis]
119 Pohlman RM, Hinshaw JL, Ziemlewicz TJ, Lubner MG, Wells SA, Lee FT Jr, Alexander ML, Wergin KL, Varghese T. Differential Imaging of Liver Tumors before and after Microwave Ablation with Electrode Displacement Elastography. Ultrasound Med Biol 2021;47:2138-56. [PMID: 34011451 DOI: 10.1016/j.ultrasmedbio.2021.03.027] [Reference Citation Analysis]
120 Gad MM, Saad AM, Faisaluddin M, Gaman MA, Ruhban IA, Jazieh KA, Al-husseini MJ, Simons-linares CR, Sonbol MB, Estfan BN. Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends. Clinics and Research in Hepatology and Gastroenterology 2020;44:885-93. [DOI: 10.1016/j.clinre.2020.03.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
121 Łapiński TW, Tarasik A, Januszkiewicz M, Flisiak R. Clinical aspects and treatment of hepatocellular carcinoma in north-eastern Poland. Clin Exp Hepatol 2021;7:79-84. [PMID: 34027119 DOI: 10.5114/ceh.2021.104631] [Reference Citation Analysis]
122 Zou RC, Li LL, Yuan HL. Current Status of Research on the Role of Circular RNAs in Hepatocellular Carcinoma and Clinical Implications. Med Sci Monit 2020;26:e923832. [PMID: 32779638 DOI: 10.12659/MSM.923832] [Reference Citation Analysis]
123 Li Q, Chen C, Zhang J, Wu H, Qiu Y, Song T, Mao X, He Y, Cheng Z, Zhai W, Li J, Zhang D, Geng Z, Tang Z. Prediction Efficacy of Prognostic Nutritional Index and Albumin-Bilirubin Grade in Patients With Intrahepatic Cholangiocarcinoma After Radical Resection: A Multi-Institutional Analysis of 535 Patients. Front Oncol 2021;11:769696. [PMID: 34956888 DOI: 10.3389/fonc.2021.769696] [Reference Citation Analysis]
124 Huang JY, Li JW, Ling WW, Li T, Luo Y, Liu JB, Lu Q. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma? World J Gastroenterol 2020; 26(27): 3938-3951 [PMID: 32774068 DOI: 10.3748/wjg.v26.i27.3938] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
125 Gijbels E, Pieters A, De Muynck K, Vinken M, Devisscher L. Rodent models of cholestatic liver disease: A practical guide for translational research. Liver Int 2021;41:656-82. [PMID: 33486884 DOI: 10.1111/liv.14800] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
126 Cheng Z, Lei Z, Jin X, Zhang Q, Si A, Yang P, Zhou J, Hartmann D, Hüser N, Shen F. Postoperative adjuvant transarterial chemoembolization for intrahepatic cholangiocarcinoma patients with microvascular invasion: a propensity score analysis. J Gastrointest Oncol 2021;12:819-30. [PMID: 34012669 DOI: 10.21037/jgo-20-443] [Reference Citation Analysis]
127 Sellers CM, Uhlig J, Ludwig JM, Stein SM, Kim HS. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease. Cancer Med. 2019;8:5916-5929. [PMID: 31429524 DOI: 10.1002/cam4.2373] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
128 Keller SB, Suo D, Wang YN, Kenerson H, Yeung RS, Averkiou MA. Image-Guided Treatment of Primary Liver Cancer in Mice Leads to Vascular Disruption and Increased Drug Penetration. Front Pharmacol 2020;11:584344. [PMID: 33101038 DOI: 10.3389/fphar.2020.584344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
129 Grissa D, Nytoft Rasmussen D, Krag A, Brunak S, Juhl Jensen L. Alcoholic liver disease: A registry view on comorbidities and disease prediction. PLoS Comput Biol 2020;16:e1008244. [PMID: 32960884 DOI: 10.1371/journal.pcbi.1008244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
130 Qin X, Song Y. Bioinformatics Analysis Identifies the Estrogen Receptor 1 (ESR1) Gene and hsa-miR-26a-5p as Potential Prognostic Biomarkers in Patients with Intrahepatic Cholangiocarcinoma. Med Sci Monit 2020;26:e921815. [PMID: 32435051 DOI: 10.12659/MSM.921815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
131 Moro A, Paredes AZ, Farooq A, Sahara K, Tsilimigras DI, Mehta R, Endo I, Guglielmi A, Aldrighetti L, Alexandrescu S, Marques HP, Shen F, Koerkamp BG, Sasaki K, Pawlik TM; other members of the International Intrahepatic Cholangiocarcinoma Study Group. Discordance in prediction of prognosis among patients with intrahepatic cholangiocarcinoma: A preoperative vs postoperative perspective. J Surg Oncol 2019;120:946-55. [DOI: 10.1002/jso.25671] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
132 Son Y, Shin NR, Kim SH, Park SC, Lee HJ. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. Int J Mol Sci 2021;22:5330. [PMID: 34069373 DOI: 10.3390/ijms22105330] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
133 Mungamuri SK, Mavuduru VA. Role of epigenetic alterations in aflatoxin‐induced hepatocellular carcinoma. Liver Cancer International 2020;1:41-50. [DOI: 10.1002/lci2.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Zhang K, Tao C, Siqin T, Wu J, Rong W. Establishment, validation and evaluation of predictive model for early relapse after R0 resection in hepatocellular carcinoma patients with microvascular invasion. J Transl Med 2021;19:293. [PMID: 34229698 DOI: 10.1186/s12967-021-02940-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Malik IA, Malik G, Ströbel P, Wilting J. Development of A New Mouse Model for Intrahepatic Cholangiocellular Carcinoma: Accelerating Functions of Pecam-1. Cancers (Basel) 2019;11:E1045. [PMID: 31344919 DOI: 10.3390/cancers11081045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
136 Hu YX, Shen JX, Han J, Mao SY, Mao RS, Li Q, Li F, Guo ZX, Zhou JH. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS. Front Oncol 2021;11:641195. [PMID: 33912456 DOI: 10.3389/fonc.2021.641195] [Reference Citation Analysis]
137 Parvinian A, Fletcher JG, Storm AC, Venkatesh SK, Fidler JL, Khandelwal AR. Challenges in Diagnosis and Management of Hemobilia. Radiographics 2021;41:802-13. [PMID: 33939540 DOI: 10.1148/rg.2021200192] [Reference Citation Analysis]
138 [DOI: 10.1101/554600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Bargellini I, Mosconi C, Pizzi G, Lorenzoni G, Vivaldi C, Cappelli A, Vallati GE, Boni G, Cappelli F, Paladini A, Sciuto R, Masi G, Golfieri R, Cioni R. Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study. Cardiovasc Intervent Radiol 2020;43:1305-14. [PMID: 32642986 DOI: 10.1007/s00270-020-02569-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
140 Huguet JM, Lobo M, Labrador JM, Boix C, Albert C, Ferrer-Barceló L, Durá AB, Suárez P, Iranzo I, Gil-Raga M, Burgos CB, Sempere J. Diagnostic-therapeutic management of bile duct cancer. World J Clin Cases 2019; 7(14): 1732-1752 [PMID: 31417920 DOI: 10.12998/wjcc.v7.i14.1732] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
141 Lonardo A, Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Targher G. Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? Dig Liver Dis 2019;51:462-70. [PMID: 30733187 DOI: 10.1016/j.dld.2018.12.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
142 Ohuchi H, Hayama Y, Nakajima K, Kurosaki K, Shiraishi I, Nakai M. Incidence, Predictors, and Mortality in Patients With Liver Cancer After Fontan Operation. J Am Heart Assoc 2021;10:e016617. [PMID: 33538186 DOI: 10.1161/JAHA.120.016617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, Jeong WK, Park MS, Kudo N, Lee MW, Kamata K, Iijima H, Kim SY, Numata K, Sugimoto K, Maruyama H, Sumino Y, Ogawa C, Kitano M, Joo I, Arita J, Liang JD, Lin HM, Nolsoe C, Gilja OH, Kudo M. The AFSUMB Consensus Statements and Recommendations for the Clinical Practice of Contrast-Enhanced Ultrasound using Sonazoid. J Med Ultrasound 2020;28:59-82. [PMID: 32874864 DOI: 10.4103/JMU.JMU_124_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
144 Fekry B, Ribas-Latre A, Baumgartner C, Mohamed AMT, Kolonin MG, Sladek FM, Younes M, Eckel-Mahan KL. HNF4α-Deficient Fatty Liver Provides a Permissive Environment for Sex-Independent Hepatocellular Carcinoma. Cancer Res 2019;79:5860-73. [PMID: 31575546 DOI: 10.1158/0008-5472.CAN-19-1277] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
145 Lei X, Zhang M, Guan B, Chen Q, Dong Z, Wang C. Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis. Hum Genomics 2021;15:39. [PMID: 34187556 DOI: 10.1186/s40246-021-00341-4] [Reference Citation Analysis]
146 Yang Y, Jin L, Tian Z, Guo D, Yao N, Li Q, Jiang Z, Yang D, Tang X, Li H, He Y, Liu J, Chen T, Zhao Y. The association of adverse outcomes in the mother with disease progression in offspring in families with clusters of hepatitis B virus infection and unfavorable prognoses in Northwest China. Medicine (Baltimore) 2018;97:e12266. [PMID: 30235671 DOI: 10.1097/MD.0000000000012266] [Reference Citation Analysis]
147 Hu J, Wang YN, Song DJ, Tan JP, Cao Y, Fan J, Wang Z, Zhou J. A High-Accuracy Model Based on Plasma miRNAs Diagnoses Intrahepatic Cholangiocarcinoma: A Single Center with 1001 Samples. Diagnostics (Basel) 2021;11:610. [PMID: 33805513 DOI: 10.3390/diagnostics11040610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
148 Hester D, Golabi P, Paik J, Younossi I, Mishra A, Younossi ZM. Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. J Clin Gastroenterol 2020;54:459-67. [PMID: 30672817 DOI: 10.1097/MCG.0000000000001172] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
149 Zhang L, Zhang B, You W, Li P, Kuang Y. Rab23 Promotes Hepatocellular Carcinoma Cell Migration Via Rac1/TGF-β Signaling. Pathol Oncol Res 2020;26:301-6. [PMID: 30191377 DOI: 10.1007/s12253-018-0463-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
150 Wang Y, Yang F, Shang J, He H, Yang Q. Integrative analysis reveals the prognostic value and functions of splicing factors implicated in hepatocellular carcinoma. Sci Rep 2021;11:15175. [PMID: 34312475 DOI: 10.1038/s41598-021-94701-8] [Reference Citation Analysis]
151 Liu X, Lu Y, Qin S. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies. Future Oncol 2021;17:2243-56. [PMID: 33663220 DOI: 10.2217/fon-2020-1290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
152 Laohawetwanit T, Lerttanatum N, Wanpiyarat N, Manasilp N, Chaiparnich S. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology. Ann Diagn Pathol 2021;53:151770. [PMID: 34147845 DOI: 10.1016/j.anndiagpath.2021.151770] [Reference Citation Analysis]
153 Schizas D, Mastoraki A, Routsi E, Papapanou M, Tsapralis D, Vassiliu P, Toutouzas K, Felekouras E. Combined hepatocellular-cholangiocarcinoma: An update on epidemiology, classification, diagnosis and management. Hepatobiliary Pancreat Dis Int 2020;19:515-23. [PMID: 32753331 DOI: 10.1016/j.hbpd.2020.07.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
154 Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, Uhrig S, Kriegsmann M, Weiss KH, Breuhahn K, Mehrabi A, Weber TF, Wilkens L, Straub BK, Rosenwald A, Schulze F, Brors B, Froehling S, Pellegrino R, Budczies J, Schirmacher P, Stenzinger A. RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut 2019;68:1287-96. [PMID: 30901310 DOI: 10.1136/gutjnl-2018-317632] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
155 Li X, Ye Z, Lin S, Pang H. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram. BMC Cancer 2021;21:701. [PMID: 34126955 DOI: 10.1186/s12885-021-08469-1] [Reference Citation Analysis]
156 Marrero JA. Surveillance for Hepatocellular Carcinoma. Clin Liver Dis 2020;24:611-21. [PMID: 33012448 DOI: 10.1016/j.cld.2020.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
157 Hoffman D, Mehta N. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol 2021;15:91-102. [PMID: 32933351 DOI: 10.1080/17474124.2021.1823213] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Rice A, Del Rio Hernandez A. The Mutational Landscape of Pancreatic and Liver Cancers, as Represented by Circulating Tumor DNA. Front Oncol 2019;9:952. [PMID: 31608239 DOI: 10.3389/fonc.2019.00952] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
159 Chen PF, Li QH, Zeng LR, Yang XY, Peng PL, He JH, Fan B. A 4-gene prognostic signature predicting survival in hepatocellular carcinoma. J Cell Biochem 2019;120:9117-24. [PMID: 30582205 DOI: 10.1002/jcb.28187] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
160 Penzkofer L, Huber T, Mittler J, Lang H, Heinrich S. [Liver Resections Can Be Safely Performed in Cirrhotic Patients after Careful Patient Selection]. Zentralbl Chir 2021. [PMID: 33663000 DOI: 10.1055/a-1373-6218] [Reference Citation Analysis]
161 Cai Z, He C, Zhao C, Lin X. Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma. Front Oncol 2021;11:611118. [PMID: 33868997 DOI: 10.3389/fonc.2021.611118] [Reference Citation Analysis]
162 Yu H, Wang H, Dong W, Cao ZY, Li R, Yang C, Cong WM, Dong H, Jin GZ. The diagnostic and prognostic value of UBE2T in intrahepatic cholangiocarcinoma. PeerJ 2020;8:e8454. [PMID: 32025379 DOI: 10.7717/peerj.8454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
163 Doan HV, Sritangos P, Iyara R, Chudapongse N. Chrysophyllum cainito stem bark extract induces apoptosis in Human hepatocarcinoma HepG2 cells through ROS-mediated mitochondrial pathway. PeerJ 2020;8:e10168. [PMID: 33088629 DOI: 10.7717/peerj.10168] [Reference Citation Analysis]
164 Bajaj G, Sundaram K, Jambhekar K, Ram R. Imaging After Locoregional Therapy for Hepatocellular Carcinoma With Emphasis on LIRADS Treatment Response Assessment Criteria. Semin Ultrasound CT MR 2021;42:390-404. [PMID: 34130851 DOI: 10.1053/j.sult.2021.03.002] [Reference Citation Analysis]
165 Singh A, Singh AK, Giri R, Kumar D, Sharma R, Valis M, Kuca K, Garg N. The role of microRNA-21 in the onset and progression of cancer. Future Med Chem 2021;13:1885-906. [PMID: 34590501 DOI: 10.4155/fmc-2021-0096] [Reference Citation Analysis]
166 Sung K, Johnston MP, Lee MY, Byrne CD. Non‐invasive liver fibrosis scores are strongly associated with liver cancer mortality in general population without liver disease. Liver Int 2020;40:1303-15. [DOI: 10.1111/liv.14416] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
167 Wang H, Wang B, Wang T, Fan R. A genetic variant in the promoter region of miR-877 is associated with an increased risk of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2020;44:692-8. [PMID: 32113822 DOI: 10.1016/j.clinre.2020.01.006] [Reference Citation Analysis]
168 Wang C, Pang S, Si-Ma H, Yang N, Zhang H, Fu Y, Yang G. Specific risk factors contributing to early and late recurrences of intrahepatic cholangiocarcinoma after curative resection. World J Surg Oncol 2019;17:2. [PMID: 30606203 DOI: 10.1186/s12957-018-1540-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
169 Vitale G, Gitto S, Campani C, Turco L, Baldan A, Marra F, Morelli MC. Biological therapies in patients with liver disease: are they really lifesavers? Expert Opin Biol Ther 2021;:1-18. [PMID: 34860629 DOI: 10.1080/14712598.2022.2013799] [Reference Citation Analysis]
170 Zheng R, Qu C, Zhang S, Zeng H, Sun K, Gu X, Xia C, Yang Z, Li H, Wei W, Chen W, He J. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin J Cancer Res. 2018;30:571-579. [PMID: 30700925 DOI: 10.21147/j.issn.1000-9604.2018.06.01] [Cited by in Crossref: 62] [Cited by in F6Publishing: 80] [Article Influence: 15.5] [Reference Citation Analysis]
171 Cao M, Ding C, Xia C, Li H, Sun D, He S, Chen W. Attributable deaths of liver cancer in China. Chin J Cancer Res 2021;33:480-9. [PMID: 34584373 DOI: 10.21147/j.issn.1000-9604.2021.04.05] [Reference Citation Analysis]
172 Zhang S, Peng R, Xin R, Shen X, Zheng J. Conjoint analysis for hepatic carcinoma with hub genes and multi-slice spiral CT. Medicine (Baltimore) 2020;99:e23099. [PMID: 33157984 DOI: 10.1097/MD.0000000000023099] [Reference Citation Analysis]
173 Zheng Y, Wu F, Rong W, Liu Y, Siqin T, Wang L, Wu J. Prognostic value of the controlling nutritional status (CONUT) score in intrahepatic cholangiocarcinoma patients especially who had long-time alcohol consumption. J Clin Biochem Nutr 2020;67:323-31. [PMID: 33293775 DOI: 10.3164/jcbn.20-27] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
174 Cheng N, Zhao H, Chen S, He Q, Cao W. Jujube honey induces apoptosis in human hepatocellular carcinoma HepG2 cell via DNA damage, p53 expression, and caspase activation. J Food Biochem 2019;43:e12998. [PMID: 31373040 DOI: 10.1111/jfbc.12998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
175 Shiota J, Samuelson LC, Razumilava N. Hepatobiliary Organoids and Their Applications for Studies of Liver Health and Disease: Are We There Yet? Hepatology 2021. [PMID: 33638203 DOI: 10.1002/hep.31772] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
176 Sabbatino F, Liguori L, Malapelle U, Schiavi F, Tortora V, Conti V, Filippelli A, Tortora G, Ferrone CR, Pepe S. Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma. Front Oncol 2020;10:567289. [PMID: 33330039 DOI: 10.3389/fonc.2020.567289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
177 Hara Y, Yamamura K, Matsumura K, Oda E, Akahoshi S, Yuki H, Tomiguchi J, Motohara T, Miyamoto H, Komohara Y, Beppu T. Laparoscopic Surgery for a Patient With Multiple Liver Metastases of Unknown Origin Concomitant With Gallbladder Tumor. In Vivo 2021;35:2963-8. [PMID: 34410995 DOI: 10.21873/invivo.12590] [Reference Citation Analysis]
178 El-far YM, Khodir AE, Emarah ZA, Ebrahim MA, Al-gayyar MMH. Fucoidan Ameliorates Hepatocellular Carcinoma Induced in Rats: Effect on miR143 and Inflammation. Nutrition and Cancer 2021;73:1498-510. [DOI: 10.1080/01635581.2020.1798478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
179 Qian F, Guo J, Jiang Z, Shen B. Translational Bioinformatics for Cholangiocarcinoma: Opportunities and Challenges. Int J Biol Sci 2018;14:920-9. [PMID: 29989102 DOI: 10.7150/ijbs.24622] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]